Clinical trial / 2021
Acarbose stimulated postprandial GLP-1 secretion and reduced postprandial glucose in patients with type 2 diabetes.
In a double-blind, placebo-controlled crossover study, 15 participants with type 2 diabetes underwent two 14-day treatment periods with acarbose or placebo. At the end of each period, participants underwent liquid mixed meal tests with concomitant infusion of the GLP-1 receptor antagonist exendin(9-39)NH2 or saline. Compared to placebo, acarbose increased postprandial GLP-1 concentrations and decreased postprandial glucose. While no absolute difference was observed in exendin(9-39)NH2-induced glucose excursions between periods, postprandial glucose relatively increased by 119 ± 116% during exendin(9-39)NH2 infusion in the acarbose period versus 39 ± 27% in the placebo period (P = 0.0163).
- Study type
- Double-blinded, placebo-controlled, randomized crossover trial
- Who was studied
- 15 participants with metformin-treated type 2 diabetes (age: 57-85 years, HbA1c: 40-74 mmol/mol)
- What was measured
- Postprandial glucose metabolism and GLP-1 concentrations during liquid mixed meal tests
THE PAPER
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
Dalsgaard NB, Gasbjerg LS, Hansen LS, Hansen NL, Stensen S, Hartmann B, Rehfeld JF, Holst JJ, Vilsbøll T, Knop FK. Eur J Endocrinol, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.